– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who

resumed revumenib post-transplant shows favorable outcomes, including a

2-year overall survival rate of 90% vs historical benchmark of 51% –

– Company also presented data highlighting unique aspects of revumenib's PK profile, including the

ability to administer it with gastric acid reducing agents without the risk of reduced efficacy –

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today highlighted key Revuforj® (revumenib) data that was presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting in Chicago, including the oral presentation of new data from the post hematopoietic stem cell transplant (HSCT) setting. Revuforj is the first and only menin inhibitor that is FDA approved for patients one year and older with relapsed/refractory (R/R) acute leukemia with a KMT2A translocation or R/R acute myeloid leukemia (AML) with a susceptible NPM1 mutation (NPM1m) who have no satisfactory alternative treatment options.